secwatch.observer — SEC 8-K summary
======================================

Issuer:     HARROW, INC. (HROW)
CIK:        0001360214
Form:       8-K
Filed at:   2025-06-09T23:59:59+00:00
Accession:  0001641172-25-014234
Event type: m_and_a
Sentiment:  positive
Materiality: 0.65
Item codes: 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Harrow licenses exclusive U.S. rights to BYQLOVI ophthalmic steroid from Formosa
--------------------------------------------------------------------------------

- Upfront payment of $500,000 at first commercial sale; additional milestone payments and royalties on gross profits.
- BYQLOVI is first new ophthalmic steroid class in over 15 years; FDA-approved for post-op inflammation/pain.
- Expected launch in Q4 2025; U.S. market exceeds 7M annual ophthalmic surgeries.
- Clinical data: 77-85% pain-free at Day 4; 1.4% elevated IOP; BID dosing 14 days without loading/maintenance.
- Formulated with Formosa's proprietary APNT nanoparticle technology.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1360214/000164117225014234/0001641172-25-014234-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1360214/000164117225014234/form8-k.htm
  HTML page:      https://secwatch.observer/filing/0001641172-25-014234

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer